<DOC>
	<DOCNO>NCT00740753</DOCNO>
	<brief_summary>Fewer 15 % hepatoma patient suitable candidate surgical removal cancer . The purpose protocol provide supervise access Oregon Health Science University Y-90 treatment provide patient access alternate therapy . The radioactive bead place directly near liver tumor intention destroy tumor cell .</brief_summary>
	<brief_title>Radiolabeled Glass Beads Used Treating Patients With Primary Liver Cancer When Surgery Not Option</brief_title>
	<detailed_description>Patients receive Y-90 ( yttrium ) glass microspheres via percutaneous hepatic arterial infusion . Patients amy retreat 30-90 day initial infusion . After completion therapy , patient follow 30 day every 3 month 2 year .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Confirmed diagnosis HCC Cancer unresectable ECOG Score 02 Age 18 yr Able give consent Contraindication angiography selective visceral catheterization Portal hypertension portal venous shunt away liver Evidence potential delivery &gt; 16.5 mCi radiation lung Evidence detectable Tc99m MAA flow stomach duodenum , application establish angiographic technique stop flow Significant extrahepatic disease represent imminent lifethreatening outcome Severe liver dysfunction pulmonary insufficiency Active uncontrolled infection Significant underlying medical psychiatric illness Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>liver tumor</keyword>
	<keyword>cancer</keyword>
	<keyword>hepatoma</keyword>
	<keyword>yttrium</keyword>
</DOC>